Pfizer SG&A Expenses 2012-2026 | PFE

Pfizer sg&a expenses for the twelve months ending March 31, 2026 were $13.724B, a 3.8% decline year-over-year.

  • Pfizer annual sg&a expenses for 2025 were $13.794B, a 6.35% decline from 2024.
  • Pfizer annual sg&a expenses for 2024 were $14.73B, a 0.28% decline from 2023.
  • Pfizer annual sg&a expenses for 2023 were $14.771B, a 8% increase from 2022.

Pfizer SG&A Expenses 2012-2026 | PFE

  • Pfizer annual sg&a expenses for 2025 were $13.794B, a 6.35% decline from 2024.
  • Pfizer annual sg&a expenses for 2024 were $14.73B, a 0.28% decline from 2023.
  • Pfizer annual sg&a expenses for 2023 were $14.771B, a 8% increase from 2022.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$887.6B
Johnson & Johnson (JNJ)$574.4B
AbbVie (ABBV)$367.7B
Roche Holding AG (RHHBY)$318.8B
Merck (MRK)$299.9B
Novartis AG (NVS)$294B
Novo Nordisk (NVO)$167.5B
Sanofi (SNY)$114B
Bayer (BAYRY)$46.2B
Innoviva (INVA)$1.8B